See more : Taurus Armas S.A. (TASA4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of cbdMD, Inc. (YCBD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of cbdMD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- BASO Precision Optics Co., LTD (6517.TWO) Income Statement Analysis – Financial Results
- TAG Immobilien AG (TAGYY) Income Statement Analysis – Financial Results
- Guangxi Wuzhou Zhongheng Group Co.,Ltd (600252.SS) Income Statement Analysis – Financial Results
- Hiroca Holdings Ltd. (1338.TW) Income Statement Analysis – Financial Results
- Yunhong International (ZGYH) Income Statement Analysis – Financial Results
cbdMD, Inc. (YCBD)
About cbdMD, Inc.
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.48M | 24.16M | 35.40M | 44.48M | 41.88M | 23.65M | 8.42M | 4.47M | 2.03M |
| Cost of Revenue | 7.49M | 9.18M | 13.07M | 14.50M | 15.51M | 9.14M | 2.67M | 1.36M | 1.62M |
| Gross Profit | 12.00M | 14.98M | 22.34M | 29.99M | 26.37M | 14.51M | 5.75M | 3.12M | 413.13K |
| Gross Profit Ratio | 61.57% | 62.01% | 63.09% | 67.41% | 62.96% | 61.37% | 68.25% | 69.71% | 20.34% |
| Research & Development | 39.02K | 173.04K | 633.39K | 1.42M | 424.45K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.44M | 9.62M | 15.81M | 21.77M | 23.06M | 0.00 | 1.79M | 0.00 | 0.00 |
| Selling & Marketing | 4.18M | 6.95M | 15.44M | 17.57M | 11.84M | 0.00 | 143.70K | 0.00 | 0.00 |
| SG&A | 12.62M | 16.55M | 31.25M | 39.34M | 34.90M | 28.88M | 1.93M | 3.36M | 0.00 |
| Other Expenses | 2.65M | 7.52M | 7.67M | 8.84M | 9.05M | 28.88M | 5.63M | 3.36M | 4.15M |
| Operating Expenses | 15.31M | 24.25M | 39.56M | 49.60M | 43.95M | 28.88M | 5.63M | 3.36M | 4.15M |
| Cost & Expenses | 22.80M | 33.42M | 52.63M | 64.10M | 59.47M | 38.01M | 8.30M | 4.71M | 5.76M |
| Interest Income | 0.00 | 63.70K | 16.25K | 28.93K | 39.88K | 75.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 16.25K | 28.93K | 0.00 | 0.00 | 955.00 | 500.63K | 154.98K |
| Depreciation & Amortization | 1.82M | 2.93M | 2.97M | 2.25M | 1.90M | 289.57K | 222.55K | 71.28K | 44.94K |
| EBITDA | -1.49M | -7.47M | -15.48M | -22.01M | -16.86M | -14.09M | -1.57M | -789.27K | -3.69M |
| EBITDA Ratio | -7.67% | -30.92% | 109.53% | -28.52% | -109.13% | 82.16% | 4.03% | -13.73% | -181.55% |
| Operating Income | -3.32M | -9.27M | 35.81M | -19.62M | -17.58M | 19.14M | 117.10K | -239.29K | -3.73M |
| Operating Income Ratio | -17.02% | -38.37% | 101.14% | -44.10% | -41.98% | 80.94% | 1.39% | -5.35% | -183.76% |
| Total Other Income/Expenses | -384.72K | -13.67M | -52.77M | -4.67M | 28.89M | -32.99M | 0.00 | -1.12M | -154.98K |
| Income Before Tax | -3.70M | -22.94M | -70.08M | -24.29M | 11.31M | -47.79M | 46.83K | -1.36M | -3.89M |
| Income Before Tax Ratio | -18.99% | -94.96% | -197.96% | -54.61% | 26.99% | -202.05% | 0.56% | -30.42% | -191.39% |
| Income Tax Expense | 0.00 | 0.00 | 4.00M | -895.00K | -1.35M | -2.36M | -16.00K | 25.00K | 8.00K |
| Net Income | -3.70M | -22.94M | -74.09M | -23.39M | 12.60M | -45.43M | -412.08K | -1.74M | -3.36M |
| Net Income Ratio | -18.99% | -94.96% | -209.26% | -52.60% | 30.09% | -192.08% | -4.89% | -38.85% | -165.22% |
| EPS | 1.93 | -13.32 | -55.80 | -19.16 | 12.47 | -114.29 | -2.39 | -10.44 | -36.58 |
| EPS Diluted | 1.93 | -13.32 | -55.80 | -19.16 | 12.19 | -114.29 | -2.39 | -10.44 | -36.58 |
| Weighted Avg Shares Out | 4.31M | 2.02M | 1.33M | 1.22M | 980.90K | 397.49K | 172.06K | 166.49K | 91.75K |
| Weighted Avg Shares Out (Dil) | 4.31M | 2.02M | 1.33M | 1.22M | 1.00M | 397.49K | 172.22K | 166.49K | 91.75K |
cbdMD Wins Awards in Two Categories at Prestigious Best in Biz Awards
Charlotte, North Carolina--(Newsfile Corp. - December 14, 2023) - cbdMD (NYSE American: YCBD), a frontrunner in the health and wellness CBD industry, is thrilled to announce that it has been named a bronze winner in two distinguished categories at the...
cbdMD Announces Cancellation of Special Meeting
Charlotte, North Carolina--(Newsfile Corp. - October 25, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) announced that it will not proceed with the vote scheduled for October 26, 2023 seeking the approval for the automatic conversion of its...
cbdMD Announces Historic Partnership with FIFA-Affiliated Costa Rican Soccer Team
Charlotte, North Carolina--(Newsfile Corp. - October 5, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one of the nation's leading providers of premium cannabidiol (CBD) products, today announced that it will be the official sponsor of...
cbdMD Announces Adjournment of Special Meeting
Scheduled to Reconvene 26, October 2023, 1:00 p.m. (Eastern Time) Charlotte, North Carolina--(Newsfile Corp. - September 22, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) announced that its Special Meeting of Shareholders that convened on September 22, 2023...
Breaking Barriers: cbdMD's Research Validates Safe CBD Upper Dose
Charlotte, North Carolina--(Newsfile Corp. - September 22, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one of the nation's leading providers of premium cannabidiol (CBD) products, today announced the publication of the Company's safety data supporting...
cbdMD, Inc. Suspends Monthly Dividend Payment on Its Series A Cumulative Convertible Preferred Stock
Charlotte, North Carolina--(Newsfile Corp. - August 22, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) today announced that its Board of Directors has suspended the monthly cash dividend payment on the Company's 8.0% Series A Cumulative Convertible Preferred Stock...
cbdMD Responds to Congressional Request for Information (RFI) on Regulation of CBD Products
Washington, D.C.--(Newsfile Corp. - August 18, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company"), one of the nation's leading providers of premium cannabidiol (CBD) products, today announced its direct response to the Bicameral and Bipartisan Congressional...
cbdMD Demonstrates Strong Year-over-Year Performance, Significantly Reducing Net Loss by $30 Million
Charlotte, North Carolina--(Newsfile Corp. - August 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator the leading CBD brands – including its flagship...
cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2023 Results
Charlotte, North Carolina--(Newsfile Corp. - August 7, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:30...
cbdMD Releases Tropical Hemp-derived THC + CBD Gummy Line to Elevate Consumer Wellness
Charlotte, North Carolina--(Newsfile Corp. - August 3, 2023) - cbdMD (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading providers of premium cannabidiol (CBD) products, today announced the launch of its hemp-derived Delta 9 THC + CBD gummies...
Source: https://incomestatements.info
Category: Stock Reports
What is cbdMD’s year-over-year reduction in net loss?
cbdMD Generates $19.1 Million in Year Over Year Reduction in Net Loss Improvement. cbdMD (NYSE: YCBD) reported significant financial improvements for fiscal year 2024, reducing its operational loss to $3.3 million, a $19.1 million year-over-year improvement from the $22.9 million loss in 2023.
What are the compliance challenges facing cbdMD with NYSE American?
However, cbdMD faces NYSE American compliance challenges, needing to increase its net book value of equity from $2.0 million to at least $4 million by December 2025 to maintain listing.